| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BLRE.2014.12.002 |
| P8608 | Fatcat ID | release_kyceo6s6frcdrb3n6wcb7zl4ry |
| P932 | PMC publication ID | 4466074 |
| P698 | PubMed publication ID | 25577686 |
| P5875 | ResearchGate publication ID | 270827044 |
| P50 | author | Srdan Verstovsek | Q64026418 |
| P2093 | author name string | Michael H Kroll | |
| Laura C Michaelis | |||
| P2860 | cites work | CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 |
| Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera | Q28174281 | ||
| Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera | Q28210331 | ||
| The haematocrit and platelet target in polycythemia vera | Q28212137 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera | Q58411917 | ||
| Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor | Q58411945 | ||
| Cathepsin G-dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell-cell adhesion | Q58412024 | ||
| Platelet activation by fMLP-stimulated polymorphonuclear leukocytes: the activity of cathepsin G is not prevented by antiproteinases | Q58412074 | ||
| Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 | ||
| Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments | Q61050105 | ||
| Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera | Q61146044 | ||
| Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 | Q62604578 | ||
| Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells | Q69102786 | ||
| Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). | Q70165797 | ||
| Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia | Q71777805 | ||
| Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis | Q73236217 | ||
| Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation | Q80575698 | ||
| Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management | Q86837757 | ||
| Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan | Q87142948 | ||
| Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin | Q28512587 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Q34037065 | ||
| Virchow's triad revisited: blood constituents | Q34391060 | ||
| Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. | Q34543068 | ||
| Risk factors for venous and arterial thrombosis | Q34988616 | ||
| Microparticles in hemostasis and thrombosis. | Q35131040 | ||
| P-selectin induces the expression of tissue factor on monocytes | Q35746146 | ||
| X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies | Q35848319 | ||
| New insights into the mechanisms of venous thrombosis | Q36068279 | ||
| Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study | Q36157668 | ||
| Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera | Q36938773 | ||
| Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a | Q37083947 | ||
| Mechanisms of venous thrombosis and resolution | Q37093456 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia | Q37349414 | ||
| Platelet adhesion to collagen | Q37824742 | ||
| Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond | Q37833893 | ||
| Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke | Q37903934 | ||
| Platelet-leukocyte interactions in thrombosis | Q37954861 | ||
| Inflammation-induced thrombosis: mechanisms, disease associations and management | Q37987961 | ||
| Front-line therapy in polycythemia vera and essential thrombocythemia | Q38025532 | ||
| Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis | Q38050141 | ||
| JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway | Q39243182 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment | Q40684511 | ||
| von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? | Q41517185 | ||
| Hematocrit and flow rate regulate the adhesion of platelets to von Willebrand factor | Q42781370 | ||
| Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. | Q44174767 | ||
| Cardiovascular events and intensity of treatment in polycythemia vera | Q44793541 | ||
| Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden | Q44900430 | ||
| Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. | Q45898721 | ||
| How I treat polycythemia vera. | Q50510659 | ||
| Role of a Janus kinase 2-dependent signaling pathway in platelet activation. | Q51741736 | ||
| Effect of hematocrit on blood pressure via hyperviscosity. | Q52209228 | ||
| Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. | Q52529694 | ||
| Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. | Q53112227 | ||
| General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. | Q53118400 | ||
| A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. | Q53312448 | ||
| Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. | Q54625613 | ||
| P433 | issue | 4 | |
| P921 | main subject | polycythemia vera | Q948318 |
| P304 | page(s) | 215-221 | |
| P577 | publication date | 2014-12-13 | |
| P1433 | published in | Blood Reviews | Q15724415 |
| P1476 | title | Mechanisms of thrombogenesis in polycythemia vera | |
| P478 | volume | 29 |
| Q42396725 | Bilateral adrenal hemorrhage in polycythemia vera. |
| Q91826612 | Comparison of Proteome Composition of Serum Enriched in Extracellular Vesicles Isolated from Polycythemia Vera Patients and Healthy Controls |
| Q50334600 | Complicated jejunal diverticulitis with unusual presentation |
| Q36443112 | Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood |
| Q26775996 | MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives |
| Q89970082 | No-reflow phenomenon during percutaneous coronary intervention in a patient with polycythemia vera: A case report |
| Q92190874 | Perioperative management of polycythemia vera with advanced gastric cancer: A case report |
| Q64231127 | Polycythemia Vera Presenting as Cardiac Arrest: Novel Management Strategies |
| Q41510435 | Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover |
| Q38811610 | Role of red blood cells in haemostasis and thrombosis |
| Q33425781 | Ruxolitinib: A Review in Polycythaemia Vera |
| Q57492711 | Takotsubo Cardiomyopathy Associated with Polycythemia Vera |
Search more.